One of the most common bacteria that cause nosocomial infections is
Klebsiella pneumonia
(
K. pneumoniae
), especially in patients who are very sick and admitted to the intensive care unit (ICU). The frequency of multi-drug-resistant
Klebsiella pneumoniae
(MDRKP) has dramatically increased worldwide in recent decades, posing an urgent threat to public health. The Western world’s bacteriophage (phage) studies have been revitalized due to the increasing reports of antimicrobial resistance and the restricted development and discovery of new antibiotics. These factors have also spurred innovation in other scientific domains. The primary agent in phage treatment is an obligately lytic organism (called bacteriophage) that kills the corresponding bacterial host while sparing human cells and lessening the broader effects of antibiotic usage on commensal bacteria. Phage treatment is developing quickly, leading to many clinical studies and instances of life-saving medicinal use. In addition, phage treatment has a few immunological adverse effects and consequences in addition to its usefulness. Since
K. pneumoniae
antibiotic resistance has made treating multidrug-resistant (MDR) infections challenging, phage therapy (PT) has emerged as a novel therapeutic strategy. The effectiveness of phages has also been investigated in
K. pneumoniae
biofilms and animal infection models. Compared with antibiotics, PT exhibits numerous advantages, including a particular lysis spectrum, co-evolution with bacteria to avoid the emergence of phage resistance, and a higher abundance and diversity of phage resources than found in antibiotics. Moreover, phages are eliminated in the absence of a host bacterium, which makes them the only therapeutic agent that self-regulates at the sites of infection. Therefore, it is essential to pay attention to the role of PT in treating these infections. This study summarizes the state of knowledge on
Klebsiella
spp. phages and provides an outlook on the development of phage-based treatments that target
K. pneumoniae
in clinical trials.
Graphical Abstract
Supplementary Information
The online version contains supplementary material available at 10.1186/s12985-024-02450-7.